Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

67,595 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Three-year clinical outcomes of the novel sirolimus-eluting bioresorbable scaffold for the treatment of de novo coronary artery disease: A prospective patient-level pooled analysis of NeoVas trials.
Wang X, Li Y, Fu G, Xu B, Zhou Y, Su X, Liu H, Zhang Z, Yu B, Tao L, Zheng Q, Li L, Xu K, Han Y; NeoVas OPC Investigators. Wang X, et al. Among authors: zhou y. Catheter Cardiovasc Interv. 2023 May;101(6):967-972. doi: 10.1002/ccd.30518. Epub 2023 Mar 7. Catheter Cardiovasc Interv. 2023. PMID: 36881746
A prospective, double-blind, randomized, controlled trial on the efficacy and cardiorenal safety of iodixanol vs. iopromide in patients with chronic kidney disease undergoing coronary angiography with or without percutaneous coronary intervention.
Nie B, Cheng WJ, Li YF, Cao Z, Yang Q, Zhao YX, Guo YH, Zhou YJ. Nie B, et al. Catheter Cardiovasc Interv. 2008 Dec 1;72(7):958-65. doi: 10.1002/ccd.21713. Catheter Cardiovasc Interv. 2008. PMID: 19021282 Clinical Trial.
Comparison of double kissing crush versus Culotte stenting for unprotected distal left main bifurcation lesions: results from a multicenter, randomized, prospective DKCRUSH-III study.
Chen SL, Xu B, Han YL, Sheiban I, Zhang JJ, Ye F, Kwan TW, Paiboon C, Zhou YJ, Lv SZ, Dangas GD, Xu YW, Wen SY, Hong L, Zhang RY, Wang HC, Jiang TM, Wang Y, Chen F, Yuan ZY, Li WM, Leon MB. Chen SL, et al. Among authors: zhou yj. J Am Coll Cardiol. 2013 Apr 9;61(14):1482-8. doi: 10.1016/j.jacc.2013.01.023. Epub 2013 Mar 10. J Am Coll Cardiol. 2013. PMID: 23490040 Free article. Clinical Trial.
A randomised comparison of a novel abluminal groove-filled biodegradable polymer sirolimus-eluting stent with a durable polymer everolimus-eluting stent: clinical and angiographic follow-up of the TARGET I trial.
Gao RL, Xu B, Lansky AJ, Yang YJ, Ma CS, Han YL, Chen SL, Li H, Zhang RY, Fu GS, Yuan ZY, Jiang H, Huo Y, Li W, Zhang YJ, Leon MB; TARGET I Investigators. Gao RL, et al. EuroIntervention. 2013 May 20;9(1):75-83. doi: 10.4244/EIJV9I1A12. EuroIntervention. 2013. PMID: 23685298 Free article. Clinical Trial.
The anatomic- and clinical-based NERS (new risk stratification) score II to predict clinical outcomes after stenting unprotected left main coronary artery disease: results from a multicenter, prospective, registry study.
Chen SL, Han YL, Zhang YJ, Ye F, Liu HW, Zhang JJ, Xu B, Jiang TM, Zhou YJ, Lv SZ. Chen SL, et al. JACC Cardiovasc Interv. 2013 Dec;6(12):1233-41. doi: 10.1016/j.jcin.2013.08.006. Epub 2013 Nov 13. JACC Cardiovasc Interv. 2013. PMID: 24239199 Free article.
Clinical Outcome After DK Crush Versus Culotte Stenting of Distal Left Main Bifurcation Lesions: The 3-Year Follow-Up Results of the DKCRUSH-III Study.
Chen SL, Xu B, Han YL, Sheiban I, Zhang JJ, Ye F, Kwan TW, Paiboon C, Zhou YJ, Lv SZ, Dangas GD, Xu YW, Wen SY, Hong L, Zhang RY, Wang HC, Jiang TM, Wang Y, Sansoto T, Chen F, Yuan ZY, Li WM, Leon MB. Chen SL, et al. Among authors: zhou yj. JACC Cardiovasc Interv. 2015 Aug 24;8(10):1335-1342. doi: 10.1016/j.jcin.2015.05.017. JACC Cardiovasc Interv. 2015. PMID: 26315736 Free article. Clinical Trial.
Safety and efficacy of zotarolimus-eluting stents in the treatment of diabetic coronary lesions in Chinese patients: The RESOLUTE-DIABETES CHINA Study.
Zhu Z, Wu Y, Shen Z, Xu Y, Li Y, Wang Y, Su X, Li B, Jiang T, Jiang J, Wang L, He S, Li X, Li H, Liu Y, Zhou Y, Tang Q, Chen Y, Fang W, Jiang L, Lu C, Guo J, Zhang J, Chen S, Xia Y, Zheng H, Wang B, Zhang D, Feng L, Tang L, Xu P, Liu X, Zhang R; RESOLUTE-DIABETES CHINA Investigators. Zhu Z, et al. Among authors: zhou y. J Diabetes. 2019 Mar;11(3):204-213. doi: 10.1111/1753-0407.12832. Epub 2018 Sep 7. J Diabetes. 2019. PMID: 30070032
Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome.
Schwartz GG, Steg PG, Szarek M, Bhatt DL, Bittner VA, Diaz R, Edelberg JM, Goodman SG, Hanotin C, Harrington RA, Jukema JW, Lecorps G, Mahaffey KW, Moryusef A, Pordy R, Quintero K, Roe MT, Sasiela WJ, Tamby JF, Tricoci P, White HD, Zeiher AM; ODYSSEY OUTCOMES Committees and Investigators. Schwartz GG, et al. N Engl J Med. 2018 Nov 29;379(22):2097-2107. doi: 10.1056/NEJMoa1801174. Epub 2018 Nov 7. N Engl J Med. 2018. PMID: 30403574 Free article. Clinical Trial.
Safety and efficacy of the novel sirolimus-eluting bioresorbable scaffold for the treatment of de novo coronary artery disease: One-year results from a prospective patient-level pooled analysis of NeoVas trials.
Xu K, Fu G, Xu B, Zhou Y, Su X, Liu H, Zhang Z, Yu B, Wang X, Han Y; NeoVas OPC Investigators. Xu K, et al. Among authors: zhou y. Catheter Cardiovasc Interv. 2019 Feb 15;93(S1):832-838. doi: 10.1002/ccd.28067. Catheter Cardiovasc Interv. 2019. PMID: 30888736
67,595 results
You have reached the last available page of results. Please see the User Guide for more information.